Microbiome News
Industry
The probiotics market grows up: from yogurt aisle to strain-level precision
“Live cultures” is becoming a measurable claim. Inside the industry shift from vague probiotics to defined, characterized strains.
Section
Industry
Probiotics, funding, deals and the companies commercialising microbiome science.
Industry
Ozempic, GLP-1 and the gut: what the microbiome has to do with the weight-loss drugs
GLP-1 is a hormone your gut already makes — and your gut bacteria help trigger it. As GLP-1 drugs reshape medicine, here is the evidence-bas…
Industry
Meet Akkermansia: the single strain dragging probiotics into the GLP-1 era
One gut bacterium has become the face of “next-generation” probiotics — a defined, characterized strain with human metabolic data and a tant…
Industry
The microbiome shakeout: when the drug startups stalled, the consumer model kept building
Between 2022 and 2024 some of the best-funded microbiome drug companies folded or sold off their crown jewels — even as the science hit its …
Industry
Flore launches what it calls the first probiotic line formulated for neurodiversity
In September 2024 the personalized-probiotics company Flore introduced a product line aimed at neurodivergent users, drawing coverage across…
Industry
Company profile: Flore’s bet on sequenced, personalized probiotics
Among the companies wagering that precision beats generic blends, Flore stands out for building formulas from an individual’s own gut sequen…
The microbiome, once a week.
The research that mattered, the hype that didn’t, and one idea worth carrying around. No spam, unsubscribe anytime.